North Star Asset Management Inc. lifted its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 15.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,721 shares of the medical research company’s stock after acquiring an additional 8,940 shares during the period. North Star Asset Management Inc.’s holdings in Edwards Lifesciences were worth $5,858,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth approximately $25,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $28,000. Dorato Capital Management acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $29,000. N.E.W. Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences by 533.9% during the fourth quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock worth $32,000 after purchasing an additional 315 shares during the period. Finally, Rakuten Securities Inc. boosted its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Price Performance
NYSE EW opened at $85.93 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.48 billion, a PE ratio of 45.71, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The company has a 50 day moving average price of $81.42 and a two-hundred day moving average price of $82.89. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $87.89.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,968 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $82.07, for a total value of $818,073.76. Following the completion of the sale, the vice president directly owned 22,798 shares in the company, valued at $1,871,031.86. The trade was a 30.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,684 shares of company stock worth $8,811,739 over the last ninety days. 0.31% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
EW has been the subject of several research reports. Piper Sandler restated an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. BTIG Research raised their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, April 24th. The Goldman Sachs Group restated a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.65.
Read Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
